Intensive blood pressure control in chronic kidney disease requires balancing volume and neurohormonal control through the use of antihypertensive medications and functional dry weight concepts.
Highlights the need to balance volume control and neurohormonal modulation for intensive blood pressure management in patients with chronic kidney disease.
Chronic kidney disease (CKD) is associated with increased risk of cardiovascular (CV) events, and the disease burden is rising rapidly. An important contributor to CV events and CKD progression is high blood pressure (BP). The main mechanisms of hypertension in early and advanced CKD are renin-angiotensin system activation and volume overload, respectively. Sodium retention is well known as a factor for high BP in CKD. However, a BP increase in response to total body sodium or volume overload can be limited by neurohormonal modulation. Recent clinical trial data favoring intensive BP lowering in CKD imply that the balance between volume and neurohormonal control could be revisited with respect to the safety and efficacy of strict volume control when using antihypertensive medications. In hemodialysis patients, the role of more liberal use of antihypertensive medications with the concept of functional dry weight for intensive BP control must be studied.
Shin et al. (Wed,) conducted a review in Chronic kidney disease and hypertension. Antihypertensive medications and volume control was evaluated. Intensive blood pressure control in chronic kidney disease requires balancing volume and neurohormonal control through the use of antihypertensive medications and functional dry weight concepts.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: